Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F-899
- Development stage
- Unknown
- Lead developer
- Evive Biotech
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
F-899 is an innovative long-acting recombinant fusion protein consisting of human growth hormone (hGH) fused to the fragment crystallizable (Fc) region of an antibody. Developed by Evive Biotech using its proprietary DiKine™ bimolecular structure platform, F-899 is expressed in Chinese hamster ovary (CHO) cells. It is designed as a therapeutic treatment for growth hormone deficiency (GHD) in children and wasting diseases. By fusing the growth hormone to an Fc domain, the drug achieves prolonged systemic exposure and a significantly extended half-life compared to native growth hormone, acting as a growth hormone receptor agonist with a reduced dosing frequency requirement.
- Other names
- Growth hormone-Fcrecombinant human growth hormone-Fc fusion proteinrhGH-Fc
02
Targets
GHR (Growth hormone receptor)
Beyond the preview
Go deeper on F-899.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F-899.